SEC Form 4 · accession 0001769529-26-000003
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kristin Patrick
Director
Period of report
Jun 24, 2026
Accepted (ET)
Jun 26, 2026 · 5:57 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.45 | Jun 24, 2026 | A | 31,746 | A | Jun 24, 2027 | Jun 23, 2036 | Common Stock | 31,746 | 31,746 | D |
Explanation of responses
- F1Option vests 100% on June 24, 2027.